(NASDAQ:CARL), CARLSBAD, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) — Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed will be presenting at the J.P. Morgan 2026 Healthcare conference on Wednesday, January 14th at 4:30-5:10 pm PT in San Francisco, CA. During the conference, Carlsmed Management will […]
(NASDAQ:IRD), RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD), (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the Compensation Committee of its Board of Directors approved an equity
Prospect Capital Announces Annual Meeting Update GlobeNewswire December 16, 2025 NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) — Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced that it held its annual meeting of stockholders (the “Annual Meeting”) on December 16, 2025. The proposals that were considered at the Annual Meeting are described
Priority Income Fund Announces Annual Meeting Update GlobeNewswire December 16, 2025 NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) — Priority Income Fund, Inc. (“Priority”, “our”, or “we”) today announced that it held its annual meeting of stockholders (the “Annual Meeting”) on December 16, 2025. The proposals that were considered at the Annual Meeting are described
Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare Conference GlobeNewswire December 16, 2025 CARLSBAD, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) — Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed will be presenting at the J.P. Morgan 2026 Healthcare conference on Wednesday, January 14th
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire December 16, 2025 RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD), (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today
RIVANNA®, developer of world-first imaging-based medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Accuro® 3S Needle Guide Kit consumables. This clearance marks a significant milestone in advancing the safety and effectiveness of ultrasound-guided needle placement. https://mma.prnewswire.com/media/2847019/RIVANNA_Logo_Logo.jpg The Accuro 3S Needle Guide Kit, designed for use
KELOWNA, BC / ACCESS Newswire / December 16, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 2,661,600 shares of its common stock, par value $0.001
(NASDAQ:CYTK), SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 15, 2025 it granted stock options to purchase an aggregate of 21,399 shares of common stock and 14,422 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 10
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire December 16, 2025 SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 15, 2025 it granted stock options to purchase an aggregate of 21,399 shares of common stock and 14,422 restricted stock units (RSUs) that